Very Long-Term Clinical Outcomes After Direct Stenting in Patients Presenting With ST-Segment Elevation Myocardial Infarction

Paola Scarparo; Riccardo Improta; Jeroen Wilschut; Isabella Kardys; Wijnand K Den Dekker; Joost Daemen; Felix Zijlstra; Nicolas M Van Mieghem; Roberto Diletti

doi:10.1016/j.carrev.2022.01.014

Very Long-Term Clinical Outcomes After Direct Stenting in Patients Presenting With ST-Segment Elevation Myocardial Infarction

Cardiovasc Revasc Med. 2022 Aug:41:144-150. doi: 10.1016/j.carrev.2022.01.014. Epub 2022 Jan 19.

Authors

Paola Scarparo¹, Riccardo Improta¹, Jeroen Wilschut¹, Isabella Kardys¹, Wijnand K Den Dekker¹, Joost Daemen¹, Felix Zijlstra¹, Nicolas M Van Mieghem¹, Roberto Diletti²

Affiliations

¹ Department of Interventional Cardiology, Thoraxcenter, Erasmus University Medical Centre, Rotterdam, the Netherlands.
² Department of Interventional Cardiology, Thoraxcenter, Erasmus University Medical Centre, Rotterdam, the Netherlands. Electronic address: r.diletti@erasmusmc.nl.

PMID: 35074298
DOI: 10.1016/j.carrev.2022.01.014

Abstract

Background/purpose: Direct Stenting (DS) could be associated with reduced distal embolization and improved reperfusion in patients with ST-segment elevation myocardial infarction (STEMI). However, the impact of DS on long-term outcomes remains unclear, therefore we evaluated the impact of DS on very long-term clinical outcome in STEMI.

Methods/materials: Between April 2002 and December 2004, patients presenting with STEMI undergoing percutaneous coronary intervention were investigated. The study population was divided into two groups: DS and conventional stenting (CS) and stratified according to initial TIMI flow. Major adverse cardiac events (MACE) were assessed at 10 years and all-cause mortality at 15 years. Cox proportional hazards models were used. When the proportional hazards assumption was not satisfied, landmark analysis at mid-term (2 years) was performed.

Results: A total of 812 consecutive patients were evaluated, 6 patients were excluded due to inadequate angiographic images, 450 (55.8%) underwent DS and 356 (44.2%) CS. At 15 years follow-up, DS was associated with a reduction in all-cause mortality (DS 35.0% vs. CS 45.3%, aHR 0.74, 95% CI 0.58-0.93, p = 0.010). The landmark analysis at 2 years identifies reduced 2-year MACE in DS compared with CS (6.8% vs.14%, aHR 0.67, 95% CI 0.49-0.93, p = 0.015) and beyond 2 years no significant differences were found between the groups (27.4% vs. 29.3%, aHR 1.00, 95% CI 0.74-1.36, p = 0.999). In patients with baseline TIMI 0-1, DS was associated with lower 10-year MACE and 15-year mortality compared with CS (aHR0.71, 95%CI 0.55-0.92, p = 0.010 and aHR0.65, 95%CI 0.50-0.84, p = 0.001, respectively).

Conclusions: DS was associated with reduced 15-year all-cause mortality and reduced mid-term MACE rate in patients with STEMI. Clinical events reduction associated with DS was particularly relevant in patients with initial TIMI flow 0-1.

Keywords: Conventional stenting; Direct stenting; Myocardial infarction; ST-segment elevation myocardial infarction; Thrombus burden.

MeSH terms

Humans
Percutaneous Coronary Intervention*
ST Elevation Myocardial Infarction* / diagnostic imaging
ST Elevation Myocardial Infarction* / therapy
Stents
Treatment Outcome